Prednisolone improves the response to primary endocrine treatment for advanced breast cancer.

Two hundred and twenty patients with progressive advanced breast cancer were given primary endocrine treatment (PET) according to menstrual status. Pre-menopausal patients received ovarian irradiation (O) and post-menopausal tamoxifen 10 mg bd (T). Patients were randomised to receive either no additional treatment or prednisolone 5 mg bd (P). Similar results were observed in each menstrual subgroup. In 194 evaluable patients, the response to PET + P was 49% and to PET alone 30% (P less than 0.01). P increased the median duration of response from 9 to 14 months (P less than 0.002) and the median time to disease progression from 5 to 9 months (P less than 0.001). Response to P after O or T alone occurred in only 2/62 (3%). Median survival in patients randomised to receive P at the outset of PET was prolonged by 4 months (P less than 0.05). The addition of P significantly improves the response to O or T in the treatment of advanced breast cancer.

• Publication year

  1988

• Venue

  British Journal of Cancer

• Publication date

  1988-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/bjc.1988.273PMID 3219274PMCID 2246832
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of prednisolone on sex hormone binding globulin during primary endocrine treatment of advanced breast cancer

  1988cited by this paper
• Pharmacology and clinical uses of inhibitors of hormone secretion and action

  1987cited by this paper
• Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells.

  1987cited by this paper
• Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens.

  1987cited by this paper
• Six-year results of a controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer

  1985cited by this paper
• Effect of prednisolone on hormone profiles during primary endocrine treatment of advanced breast cancer.

  1984cited by this paper
• Contribution of prednisolone to the primary endocrine treatment of advanced breast cancer.

  1982cited by this paper
• Estrogen and progesterone receptors: Correlation of response rates, site and timing of receptor analysis

  1982cited by this paper
• Corticosteroids for elderly patients with breast cancer

  1981cited by this paper
• Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast.

  1979cited by this paper
• Ovarian irradiation and prednisone therapy following surgery and radiotherapy for carcinoma of the breast.

  1979cited by this paper
• Assessment of response to therapy in advanced breast cancer.

  1977cited by this paper

• Fasting boosts breast cancer therapy efficacy via glucocorticoid activation

  2025cites this paper
• Inhibition of the NRF2/KEAP1 Axis: A Promising Therapeutic Strategy to Alter Redox Balance of Cancer Cells

  2021cites this paper
• Effect of glucocorticoid use on survival in patients with stage I–III breast cancer

  2018cites this paper
• Systemic Therapy of Bone Metastases

  2014cites this paper
• Combination anastrozole and fulvestrant in metastatic breast cancer.

  2012cites this paper
• Role of glucocorticoids in breast cancer.

  2010cites this paper
• Hormonotherapy of Bone Metastases

  2009cites this paper
• Targeted delivery of anti-inflammatory agents to tumors.

  2009cites this paper
• Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy

  2008cites this paper
• Glucocorticoid receptor changes its cellular location with breast cancer development.

  2008cites this paper
• Dexamethasone stimulation of retinoic Acid-induced sodium iodide symporter expression and cytotoxicity of 131-I in breast cancer cells.

  2006cites this paper
• Breast Cancer: An Overview

  2005cites this paper
• Clinical Utility of Aromatase Inhibitors

  2002cites this paper
• Expression of the 11beta-hydroxysteroid dehydrogenase type II enzyme in breast tumors and modulation of activity and cell growth in PMC42 cells.

  2001cites this paper
• Estradiol inhibits glucocorticoid receptor expression and induces glucocorticoid resistance in MCF-7 human breast cancer cells.

  2001cites this paper
• Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group.

  1999cites this paper
• Locally advanced breast cancer.

  1999cites this paper
• Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.

  1998cites this paper
• Issues concerning the role of chemotherapy and hormonal therapy of bone metastases from breast carcinoma.

  1997cites this paper
• Inhibition of 11 beta-hydroxysteroid dehydrogenase activity enhances the antiproliferative effect of glucocorticosteroids on MCF-7 and ZR-75-1 breast cancer cells.

  1997cites this paper
• Issues concerning the role of chemotherapy and hormonal therapy of bone metastases from breast carcinoma

  1997cites this paper
• [Hormone therapy of breast cancer in the metastatic phase in menopausal women].

  1996cites this paper
• Treatment of metastatic breast cancer: present and future prospects.

  1995cites this paper
• Mechanisms of action of endocrine treatment in breast cancer.

  1995cites this paper
• [Endocrine therapy of progressive breast carcinoma].

  1995cites this paper
• Total suppression of spontaneous endometrial carcinoma in BDII/Han rats by melengestrol acetate.

  1995cites this paper
• Angiogenesis and breast cancer.

  1994cites this paper
• A controlled trial of adjuvant tamoxifen, with or without prednisolone, in post-menopausal women with operable breast cancer.

  1994cites this paper
• Metastatic Bone Disease

  1994cites this paper
• Systemic Treatment of Bone Metastases: Review of Literature and Retrospective Analysis of 718 Breast Cancer Patients

  1994cites this paper
• Dose response in the treatment of breast cancer.

  1994cites this paper
• Use of endocrine therapy to study the biology of breast cancer.

  1993cites this paper
• Review article : Hormone treatments in the common 'hormone-dependent' carcinomas

  1993cites this paper
• Improving treatment for advanced breast cancer.

  1993cites this paper
• The influence of adjuvant chemotherapy on outcome after relapse for patients with breast cancer.

  1993cites this paper
• Glucocorticoids in cancer therapy

  1992cites this paper
• Prednisolone in the treatment of severe malignant hypercalcaemia in metastatic breast cancer: a randomized study

  1992cites this paper
• Tamoxifen protects against steroid-induced bone loss.

  1992cites this paper
• The Systemic Treatment of Bone Metastases

  1991cites this paper
• Bone Metastases

  1991cites this paper
• A double‐blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. A collaborative trial of the north central cancer treatment group and mayo clinic

  1991cites this paper
• New endocrine drugs for treatment of advanced breast cancer.

  1990cites this paper
• Tamoxifen as an Agonist for Metastatic Breast Cancer

  1990cites this paper
• Management of advanced breast cancer.

  1989cites this paper
• The use of endocrine therapy.

  1989cites this paper
• Prednisolone enhancement of primary endocrine anticancer treatment: a possible anti-angiogenic effect.

  1989cites this paper
• Norethisterone acetate as secondary endocrine treatment in advanced breast cancer.

  1989cites this paper